Triple-negative breast cancer (TNBC) metastasizes and is currently associated with poor prognosis and lack of effective targeted therapies. We are studying the potential of Deferiprone, an intracellular iron chelator clinically used for non-cancer-related diseases, to improve the chemotherapeutic treatment response in TNBC by altering cellular iron-dependent proliferation and metabolism. Here, cellular and energy metabolism changes in response to Deferiprone were assayed in live TNBC cells by multi-nuclear MRS in our MR-compatible bioreactor. Metabolic changes in a human TNBC cell line are compared to previous findings in murine TNBC cells.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords